# US 2025/0051420 A1 · RECOMBINANT pMHC CLASS II MOLECULES

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0051420 A1
- Document ID: US20250051420A1
- Status: Published application
- Kind: A1
- Application number: 18/810,261
- Filed: 2024-08-20
- Published: 2025-02-13
- Earliest claimed: 2016-11-09
- Applicants: UTI Limited Partnership
- Inventors: Pedro SANTAMARIA
- Web page: https://patentgrep.com/patent/US20250051420A1

## CPC

- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 47/551: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/605: {MHC molecules or ligands thereof}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are heterodimers containing at least one first polypeptide and at least one second polypeptide, wherein the first polypeptide and the second polypeptide meet at an interface, wherein the interface of the first polypeptide contains an engineered protuberance which is positionable in an engineered cavity in the interface of the second polypeptide; and (i) the first polypeptide contains an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; or (ii) the first polypeptide contains an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof.

## Claims

### Claim 1

A composition comprising at least one isolated heterodimer conjugated to a nanoparticle,
wherein the nanoparticle is non-liposomal and/or has a solid core and
wherein the isolated heterodimer comprises at least one first polypeptide, at least one second polypeptide and an autoimmune disease-relevant antigen, wherein the first polypeptide and the second polypeptide meet at an interface, wherein the interface of the first polypeptide comprises an engineered protuberance which is positionable in an engineered cavity in the interface of the second polypeptide,
wherein the engineered protuberance comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 54,
wherein the engineered cavity comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 52; wherein
(i) the first polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; or
(ii) the first polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof;
wherein the autoimmune disease-relevant antigen is a polypeptide which is at least 11 amino acids in length connected to the MHC class II α1 domain or the MHC class II β1 domain by a flexible linker; and
wherein neither the first polypeptide nor the second polypeptide comprises a leucine zipper domain, or an extraneous biotinylation site or purification tag.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The composition of claim 1, wherein the engineered protuberance comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 54.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the engineered protuberance comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 54.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The composition of claim 1, wherein the engineered cavity comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 51 or SEQ ID NO: 52.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the engineered cavity comprises an amino acid sequence that is at least 98% identical to the amino acid sequence set forth in SEQ ID NO:51 or SEQ ID NO: 52.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The composition of claim 1, wherein the solid core is a gold, iron, or iron oxide core.

### Claim 28 (depends on 1)

The composition of claim 1, wherein the solid core has a diameter of less than 100 nanometers.

### Claim 29

(canceled)

### Claim 30 (depends on 1)

The composition of claim 1, wherein the at least one heterodimer is covalently linked to the nanoparticle through a linker comprising polyethylene glycol (PEG).

### Claim 31 (depends on 30)

The composition of claim 30, wherein the polyethylene glycol is functionalized with maleimide.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the polyethylene glycol is less than 5 kD.

### Claim 33 (depends on 1)

A pharmaceutical composition comprising the composition of claim 1, and a pharmaceutical excipient, stabilizer, or diluent.

### Claim 34

(canceled)

### Claim 35 (depends on 33)

A method of treating an autoimmune disease or inflammatory condition comprising administering to an individual the composition of claim 33.

### Claim 36

A method of preparing a heterodimer comprising a first polypeptide, a second polypeptide, and an autoimmune disease-relevant antigen, wherein
the first polypeptide and the second polypeptide meet at an interface, wherein the interface of the first polypeptide comprises an engineered protuberance which is positionable in an engineered cavity in the interface of the second polypeptide;
wherein the engineered protuberance comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 54,
wherein the engineered cavity comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 52; wherein
(i) the first polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; or
(ii) the first polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof;
wherein the autoimmune disease-relevant antigen is a polypeptide which is at least 11 amino acids in length connected to the MHC class II α1 domain or the MHC class II β1 domain by a flexible linker; and
wherein neither the first polypeptide nor the second polypeptide comprises a leucine zipper domain, or an extraneous biotinylation site or purification tag;
comprising the steps of:
(i) culturing a host cell comprising a nucleic acid encoding the first polypeptide and second polypeptide including the interfaces thereof, wherein the nucleic acid encoding the interface of the first polypeptide has been altered from nucleic acid encoding an original interface of the first polypeptide to encode the protuberance, the nucleic acid encoding the interface of the second polypeptide has been altered from nucleic acid encoding an original interface of the second polypeptide to encode the cavity, or both, and wherein the culturing is such that the first polypeptide and second polypeptide are expressed; and
(ii) recovering and purifying the heterodimer from the host cell culture.

### Claim 37

A method of preparing a heterodimer comprising a first polypeptide, a second polypeptide, and an autoimmune disease-relevant antigen, wherein
the first polypeptide and the second polypeptide meet at an interface, wherein the interface of the first polypeptide comprises an engineered protuberance which is positionable in an engineered cavity in the interface of the second polypeptide;
wherein the engineered protuberance comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 54,
wherein the engineered cavity comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 52; wherein
(i) the first polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; or
(ii) the first polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof;
wherein the autoimmune disease-relevant antigen is a polypeptide which is at least 11 amino acids in length connected to the MHC class II α1 domain or the MHC class II β1 domain by a flexible linker; and
wherein neither the first polypeptide nor the second polypeptide comprises a leucine zipper domain, or an extraneous biotinylation site or purification tag;
comprising the steps of:
(i) culturing a first host cell comprising a nucleic acid encoding the first polypeptide;
(ii) culturing a second host cell comprising a nucleic acid encoding the second polypeptide;
(iii) recovering the first and second polypeptides from the host cell cultures; and
(iv) forming the heterodimer by incubating the first and second polypeptides together;
wherein the nucleic acid encoding the interface of the first polypeptide has been altered from nucleic acid encoding an original interface of the first polypeptide to encode the protuberance, the nucleic acid encoding the interface of the second polypeptide has been altered from nucleic acid encoding an original interface of the second polypeptide to encode the cavity, or both.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43 (depends on 5)

The composition of claim 5, wherein the engineered protuberance comprises an amino acid sequence that is the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 54.

### Claim 44 (depends on 10)

The composition of claim 10, wherein the engineered cavity comprises an amino acid sequence that is the amino acid sequence of SEQ ID NO: 51 or SEQ ID NO: 52.
